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Background: Nanosuspensions are an important class of delivery system for vaccine adjuvants and drugs.
Previously, we developed a nanosuspension consisting of the synthetic TLR4 ligand glucopyranosyl lipid adjuvant
(GLA) and dipalmitoyl phosphatidylcholine (DPPC). This nanosuspension is a clinical vaccine adjuvant known as
GLA-AF. We examined the effects of DPPC supplier, buffer composition, and manufacturing process on GLA-AF
physicochemical and biological activity characteristics.
Results: DPPC from different suppliers had minimal influence on physicochemical and biological effects. In general,
buffered compositions resulted in less particle size stability compared to unbuffered GLA-AF. Microfluidization
resulted in rapid particle size reduction after only a few passes, and 20,000 or 30,000 psi processing pressures were
more effective at reducing particle size and recovering the active component than 10,000 psi. Sonicated and
microfluidized batches maintained good particle size and chemical stability over 6 months, without significantly
altering in vitro or in vivo bioactivity of GLA-AF when combined with a recombinant malaria vaccine antigen.
Conclusions: Microfluidization, compared to water bath sonication, may be an effective manufacturing process to
improve the scalability and reproducibility of GLA-AF as it advances further in the clinical development pathway.
Various sources of DPPC are suitable to manufacture GLA-AF, but buffered compositions of GLA-AF do not appear
to offer stability advantages over the unbuffered composition.Introduction
TLR ligands represent an important class of immuno-
modulators that are utilized to enhance and shape im-
mune responses to recombinant vaccine antigens. In
fact, the TLR4 ligand monophosphoryl lipid A (MPL®), a
component of the human papilloma virus vaccine Cer-
varix®, is one of the few adjuvant molecules employed in
an FDA-approved human vaccine. The importance of
formulation effects on the stability and biological activity
of TLR ligands is increasingly being recognized [1,2].
Moreover, differences in vaccine antigen structures may
necessitate adjuvant formulation development to optimize
antigen-adjuvant compatibility and immunogenicity [3].
We have developed various clinical and preclinical nano-
formulations of the synthetic TLR4 ligand glucopyranosyl* Correspondence: cfox@idri.org
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stated.lipid adjuvant (GLA) [2,4-6]. Since GLA is hydrophobic,
appropriate formulation is critical to stably disperse the
molecule in aqueous solution. A widely used approach for
similarly insoluble molecules is to create a nanoscale
aqueous suspension by adding a surfactant, such as a
phospholipid, to the insoluble molecule before rehydrating
in water. Aqueous nanosuspensions of vaccine adjuvants
have shown immunological potency with various antigens,
and have progressed to clinical trials [7]. Furthermore, they
contain few excipients and are straightforward to manufac-
ture. From a global health perspective, aqueous nanosus-
pensions present a very appealing option as a vaccine
adjuvant product due to low manufacturing cost.
We have developed an aqueous nanosuspension of GLA
(GLA-AF) prepared by first co-dissolving GLA and 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) at a
1:2 molar ratio in chloroform. The organic solvent is
then evaporated, leaving a film of the TLR ligand andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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resulting suspension is created via bath sonication at ~60°C
until the formulation is transparent. Previous studies indi-
cate that GLA-AF particle structure is somewhat heteroge-
neous, consisting of micelles, disks, and vesicles [8,9]. This
heterogeneous composition may in part be the result of the
sonication manufacturing process. While sonication is con-
venient for small batch sizes (~10 ml), sonication parame-
ters may not be straightforward to scale up and energy
input may not be uniform throughout the sonicated batch.
Larger batch sizes or concentrated GLA-AF suspensions
may require ≥4 hours of sonication and heating, which
is undesirable since prolonged processing and heating of
some suspensions may result in component degradation
[10]. An alternative formulation processing method is a
form of high pressure homogenization called microflui-
dization. Microfluidization relies on shear forces gener-
ated by passing the formulation through narrow orifices
at high pressure. This method may reduce processing
time compared to sonication; in addition, the microflui-
dization interaction chamber provides a controlled en-
forcement of particle size decrease, which may result in a
more homogeneous formulation and reduce the potential
for component degradation due to over-processing [11].
Furthermore, processing by microfluidization allows for
straightforward scale up, and can more easily be tailored
for sterile production than sonication [11].
This study aims to optimize GLA-AF by replacing sonic-
ation processing with a microfluidization-based approach.
We also investigate the effects of different buffer compo-
sitions and DPPC from several different suppliers. In or-
der to develop a new composition and/or manufacturing
method for GLA-AF, we determined that it must meet or
exceed the expected physical and chemical stability, and re-
tain the same biological activity, as GLA-AF prepared in
the traditional manner as described above. In order to
examine the interactions between the TLR ligand, phospho-
lipid, and aqueous phase, extensive analytical characteriza-
tion is necessary. We have employed a suite of analytical
techniques that are useful for analysis of nanosuspensions,
including dynamic light scattering (DLS), HPLC, and differ-
ential scanning calorimetry (DSC), which together provide
essential data regarding particle size, size polydispersity,
component concentration and purity, chemical stability,
and lipid phase conformation. Besides evaluating the stabil-
ity of the formulations produced, we have investigated their
innate adjuvant activity on in vitro human cells as well as
their in vivo biological activity as vaccine adjuvants with a
model recombinant antigen in the murine model.
Materials and methods
Adjuvant formulation materials and manufacture
Synthetic monophosphoryl lipid A (glucopyranosyl lipid
adjuvant or GLA) was purchased from Avanti Polar LipidsInc. (Alabaster, AL). 1,2-dipalmitoyl-sn-glycero-3-phospha-
tidylcholine (DPPC) was purchased from four different sup-
pliers: Avanti Polar Lipids Inc. (Alabaster, AL), Corden
Pharma (Liestal, Switzerland), Lipoid LLC (Newark, NJ),
and NOF Corporation (Kawasaki, Japan). Monobasic and
dibasic ammonium phosphate, monobasic potassium phos-
phate, dibasic sodium phosphate, and monohydrate citric
acid were purchased from J.T. Baker (San Francisco, CA).
Phosphate buffered saline 1× (PBS) at pH 7.2 was pur-
chased from Invitrogen (Grand Island, NY). Sodium chlor-
ide and HEPES were purchased from Sigma-Aldrich (St.
Louis, MO).
GLA-AF at 0.25 or 1 mg/ml GLA was manufactured by
first combining GLA and DPPC at a 1:2 molar ratio (GLA:
DPPC) in excess chloroform in 10-ml vials, which were
then evaporated using a Genevac EZ-2 Plus Evaporator
(Stone Ridge, New York) or a Buchi Rotavapor R-114
(Flawil, Switzerland). Vials containing the dried DPPC and
GLA were rehydrated in 10 ml ultrapure water per vial,
then sonicated in a VWR 75D (West Chester, PA) or Crest
Powersonic CP230D (Trenton, NJ) sonicating water bath
at ~60°C for ~1-2 hours or until the formulation was trans-
lucent with no visible particles. All buffered GLA-AF
formulations were manufactured at 1 mg/ml GLA. Manu-
facture procedure is the same as above, except the dried
DPPC and GLA were rehydrated in 10 ml of the following-
buffers instead of ultrapure water: ammonium phosphate
(5, 12.5, 20, 25 mM, pH ~5.5); citric acid (10 mM, pH 6.1);
phosphate-buffered saline (composed of 1.5 mMmonobasic
potassium phosphate, 155 mM sodium chloride, and
2.7 mM dibasic sodium phosphate, at pH 7.2; or 41 mM
monobasic potassium phosphate, 103 mM sodium chloride,
and 9 mM dibasic sodium phosphate, at pH 6.1); HEPES
(10 mM, pH 7); and HEPES-buffered saline (10 mM
HEPES, 154 mM NaCl, pH 7). Buffer compositions (and
pH values) were selected based on existing clinical adjuvant
formulations or in related literature of interest. Thus, am-
monium phosphate is the buffer employed in IDRI’s emul-
sion adjuvant (SE or GLA-SE) currently in clinical trials [6].
The 10 mM citrate buffer is the buffer in Novartis’
emulsion adjuvant, MF59® [12]. The PBS formulation with
pH 6.1 is the buffer used in GlaxoSmithKline’s liposome
adjuvant, AS01 [13]. The 10 mM HEPES buffers were moti-
vated based on favorable performance (compared to PBS)
in the manufacture of DPPC dispersions reported pre-
viously [14]. The ammonium phosphate buffer was pre-
pared at four different strengths to evaluate the effect of
buffer strength. The sonicated formulations were filtered
using a Pall Life Sciences, Acrodisc® syringe filter, 0.2-μm
Supor® membrane (Port Washington, NY).
Aqueous formulations made by microfluidization were
prepared in a similar way as described above up to the
point of chloroform evaporation on the Genevac EZ-2 Plus
Evaporator (Stone Ridge, New York). The vial containing
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then briefly sonicated (~5 minutes) in a VWR 75D (West
Chester, PA) or Crest Powersonic CP230D (Trenton, NJ)
sonicating water bath at 60°C until the dried GLA-DPPC
mixture was removed from the sides of the glass vial. The
pre-processed formulation was diluted with ultrapure water
to reach final theoretical concentrations of 0.25 mg/ml, 0.1
or 0.025 mg/ml GLA. The Microfluidics M110P (Newton,
MA), equipped with a diamond F12Y interaction chamber
followed in series by a ceramic H30Z auxiliary processing
module, was employed for processing the formulations at
three different pressures: 10,000, 20,000, and 30,000 psi for
up to 20 discrete passes with recirculating chilled water
to prevent excessive temperature increase during process-
ing. To determine the optimum processing conditions for
manufacturing GLA-AF, the 0.1 mg/ml GLA-AF was proc-
essed at 3 different pressures and 50-μl aliquots were re-
moved after each pass up to 20 passes for particle size
characterization by dynamic light scattering as described
below. The remaining formulation after the 20th pass for
each pressure was placed on a standard stability measure-
ment schedule at the time of manufacture and 1 week,
2 week, 1 month, 3 months, and 6 months thereafter to
monitor particle size and GLA concentration. Buffered
GLA-AF (12.5 mM ammonium phosphate) was also pre-
pared by microfluidization. Buffered GLA-AFs were pre-
pared in the same way as the unbuffered GLA-AF up to
the point of rehydration. The ammonium phosphate
GLA-AF was manufactured at 0.1 mg/ml GLA and
processed at 20,000 and 30,000 psi up to 10 passes each
on the microfluidizer with aliquots removed at the 2nd
and 10th passes for stability assays. Selected microfluidized
GLA-AF batches were filtered through a 0.2-μm Supor®
membrane prior to in vivo biological activity evaluation.
Dynamic light scattering particle size analysis
Particle size for each formulation was determined using
the Malvern Instruments (Worcestershire, UK) Zetasizer
Nano-S or –ZS via dynamic light scattering (DLS). 50 μl
of GLA-AF were combined with 450 μl ultrapure water
in a 1.5-ml polystyrene disposable cuvette. DLS mea-
surements were made three times on each cuvette.
HPLC-CAD analysis
To prepare GLA-AF samples, the formulation was diluted
1:20 or 1:5 (depending on target GLA concentration) into
mobile phase A (75:15:10 [v:v:v] methanol:chloroform:
water with 20 mM ammonium acetate and 1% acetic acid).
For each formulation, three separate vials were prepared.
All samples were injected at 50-μl volume onto a Waters
Co. (Milford, MA) XBridge BEH Shield RP18 column at-
tached to an Agilent Model 1100 HPLC (Santa Clara, CA).
A gradient consisting of mobile phases A and B (1:1 [v:v]
methanol:chloroform with 20 mM ammonium acetate and1% acetic acid) was employed over 25 minutes. Detection
was performed by an ESA Biosciences (Chelmosford, MA)
Corona Charged Aerosol Detector (CAD). Quantitation
was performed using a GLA standard injected at different
volumes in mobile phase B to create a standard curve.
Due to assay variation, a +/− 20% of target value is
employed as the specification for detecting meaningful
change in GLA concentration.
Differential scanning calorimetry
Thermal phase transition profiles for sonicated and micro-
fluidized 0.1 mg/ml GLA-AF batches were determined
using the MicroCal VP-DSC (Northampton, MA). Ultra-
pure pure water was used as reference for all GLA-AF
samples. All references and samples were degassed using
the MicroCal ThermoVac (Northampton, MA) at 24°C
for 5 minutes before loading into the reference and sam-
ple cells. For each lot analyzed, scans were performed in
the Identical Scan Mode from 5°C to 60°C at a scan rate
of 60°/hr.
In vitro whole blood stimulation
Formulations were prepared in 1.5-ml capacity eppi-tubes
by diluting with phosphate buffered saline (PBS) pH 7.2
purchased from Life Technologies (Grand Island, NY),
thereby standardizing the GLA concentration for each for-
mulation at 6 μg in a total volume of 1 ml. 150 μl of each
formulation were plated in duplicate into 96-well round-
bottom tissue culture plates, followed by seven 1:3 serial di-
lutions in PBS, resulting in final well volumes of 100 μl and
spanning a GLA concentration range between 1 – 3000 ng/ml.
Next, 100 μl of heparinized whole blood (obtained
with informed consent from three healthy volunteers)
were added to each well, then incubated at 37°C and 5%
CO2 for 24 hrs. After incubation, the plates were micro-
centrifuged for ten minutes at 1600 RPM and two 50-μl
extractions of the plasma supernatant from each well
were carefully obtained and assayed for cytokine con-
tent per manufacturer’s instructions, using ELISA kits for
MIP-1β and IL-12p40 from R&D Systems (Minneapolis,
MN). Standards were prepared in triplicate (plated sepa-
rately from the formulation-stimulated supernatants) according
to the respective ELISA protocols, spanning a range of 0.008 –
1 ng/ml for MIP-1 β and 0.031 – 4 ng/ml for IL-12p40.
In vitro mono mac 6 cell line stimulation
Cell culture, maintenance and in vitro stimulation set-up
of the human acute monocytic leukemia cell line from
Leibniz-Institute DSMZ (Braunschweig, Germany) were
performed as instructed by the supplier’s protocol up to
a week in advance of planned stimulation. Formulations
were prepared in 1.5-ml capacity eppi-tubes by diluting
with Mono Mac 6 cell media, standardizing the GLA
concentration for each formulation at 6 μg in a total
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plated in duplicate into 96-well round-bottom tissue cul-
ture plates, followed by seven 1:3 serial dilutions with
Mono Mac 6 cell media, giving final well volumes of
120 μl and spanning a GLA concentration range bet-
ween 1 – 3000 ng/ml. Next, 100 μl from each well were
transferred to a separate well pre-plated with 100 μl (1–
2 × 105 cells) of Mono Mac 6 cells and incubated at 37°C
and 5% CO2 for 24 hrs. After incubation, the plates were
microcentrifuged for ten minutes at 1600 RPM and 75 μl
of the supernatant were extracted from each well and
assayed for cytokine content using the ELISA kit from
R&D Systems (Minneapolis, MN) for MIP-1β. Standards
template applied to this assay was obtained from the MIP-
1β ELISA run described above for the whole blood stimu-
lation assay.
Mouse immunizations and immune response analysis
Plasmodium berghei circumsporozoite protein (PbCSP)
was expressed and purified from E. coli using the codon-
harmonized construct kindly provided by Dr. Evelina
Angov from the Walter Reed Army Institute of Research.
All animal protocols were approved by the IDRI institu-
tional animal care and use committee. Female C57BL/6
mice were purchased from Charles River Laboratories
(Wilmington, MA) and maintained in specific pathogen-
free conditions. Mice, 6–8 weeks of age and 4–5 mice per
group, were immunized a total of three times at two-week
intervals by injection into the quadricep. For immuni-
zation, recombinant protein was formulated with adjuvant
to provide a total of 2 μg protein/injection with 1 μg GLA
in a total volume of 0.1 ml.
Blood was collected from the retro-orbital sinus two
weeks after the second immunization and processed
using Microvette 200 Z-Gel (SARSTEDT AG & Co.,
Numbrecht, Germany) according to the manufacturer's
recommendation. Sera were subsequently stored at 4°C
until antigen-specific antibody responses were deter-
mined by ELISA. Corning 384-well High Binding Plates
(Corning, Rochester, NY) were coated overnight with
1 μg/ml PbCSP antigen in Ebioscience 0.1 M PBS coating
buffer. Plates were washed using PBS/0.05% Tween 20 and
blocked greater than 2 hours at room temperature with 1%
BSA-PBS 0.05% Tween. Following washes in PBS/Tween,
mouse serum was added and serially diluted starting with
first well (1:100) 1 to 4 in plate using Saigen Multipette® 96
channel Robotic platform. After primary incubation and
further washes, either anti-mouse IgG-HRP, anti-mouse-
IgG2c-HRP or anti-mouse IgG1-HRP were added (all
Southern Biotech, Birmingham, AL). After 1 hour incuba-
tion at room temperature and washing, Sure Blue™ TMB
(Kirkegaard and Perry Laboratories, Gaithersburg, MD)
microwell Peroxidase was added to each well to reveal
reactions, which were then stopped by the addition of 1 NH2SO4. Plates were analyzed at 450-570 nm (Synergy
HT, Bio-Tek Instruments Inc, Winooski, VT). Endpoint
titer was determined by Graph Prism nonlinear regres-
sion (curve fit) sigmoidal dose response (variable slope)
to interpolate unknowns from the last optical density (OD)
value greater than a threshold determined by sera from un-
immunized mice.
One month after the final immunization, spleens were re-
moved and single cell suspensions prepared. Mononuclear
cells were enumerated using aViaCount assay with a Guava
Easy cyte HT (Guava Technologies, Hayward, CA), resu-
pended in RPMI-1640 supplemented with 10% heat-
inactivated FBS and 100 Units penicillin/streptomycin
(Gemini Bio-Products). To measure cytokine production,
mononuclear cells were incubated at 2 × 105 cells per well
in duplicate in a 96-U Bottom well plate (Corning Incorpo-
rated, Corning, NY) in the presence of 10 μg/ml protein for
4 days, after which supernatants were collected and IFNγ/
IL-5 content determined by ELISA according to the manu-
facturer’s instructions (eBioscience, San Diego, CA).
To determine the number of cells producing each cyto-
kine, multiScreen 96-well filter plates 0.45 μm Hydophobic
High Protein Binding Immobion-P Membrane (Millipore)
were coated with rat anti-mouse IL-5 or rat anti-mouse
IFNγ capture antibody (both eBioscience) according to
manufacturer’s recommendation and incubated overnight
at 4˚C. Plates were washed with PBS, blocked with RPMI
1640 containing 10% FBS 100 units penicillin/streptomycin
for at least 1 h 37˚C, and washed again. Spleen cells
were then added at 2 × 105 cells/well (100 ul) and incu-
bated with media, PbCSP (10 μg/ml) or Concavalin A
(1.5ug/ml) Sigma (for 48 h at 37°C). The plates were
then washed with PBS–0.1% Tween 20 and incubated
with a biotin-conjugated rat anti-mouse IL-5 or IFNγ
secondary antibody (eBioscience) diluted in 5× Assay
Buffer (eBioscience). The filters were developed using the
Vectastain AEC substrate kits according to the manufac-
turer’s protocol (Vector Laboratories, Burlingame, CA).
Reactions were stopped by washing with deionized water,
then plates were dried in the dark and spots were
enumerated using an automated ELISPOT reader (CTL
Immunospot; Cellular Technology Ltd., Shaker Heights,
OH) and analyzed with ImmunoSpot software (Cellular
Technology Ltd).
Results and discussion
In general, GLA-AF preparations were examined for the
following indicators of formulation stability: visual appea-
rance, particle size, and GLA concentration. Particle size,
based on scattering intensity (Z-ave) and polydispersity
index (PdI), was measured via dynamic light scattering.
GLA concentration was measured via HPLC with charged
aerosol detection (CAD). Visual appearance and particle
size were examined on the date of manufacture (DM), and
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Figure 1 HPLC-CAD profiles of DPPC from four different suppliers indicate comparable raw material purity.
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1 month, 3 months, and 6 months. GLA concentration
was measured on the DM and at 6 months. We consi-
dered GLA-AF to be unstable if at least one of the follo-
wing conditions occurred for each batch of manufactured
formulation: visual appearance that was not indicative of
homogeneous, translucent solution (i.e. presence of large
visible particulates); particle size change of more than 50%
of the particle size on the DM; GLA concentration change
of more than 20% of the GLA concentration on the DM.
Upon failing a stability test, the formulation was removed
from testing and not measured at subsequent timepoints.
Influence of DPPC from different manufacturers on
physicochemical stability
Two separate batches of GLA-AF employing DPPC from
each of four different DPPC suppliers were preparedTable 1 Effect of DPPC from different suppliers on GLA-AF ph
DPPC supplier Particle size (Z-ave, nm) Pdl
DM 6 mo DM 6 mo
NOF Lot 1 85 ± 2 87 ± 3 0.27 ± 0.01 0.27 ± 0.0
Lot 2 78 ± 1 81 ± 2 0.31 ± 0.03 0.33 ± 0.0
Corden Lot 1 88 ± 3 89 ± 2 0.28 ± 0.03 0.26 ± 0.0
Lot 2 102 ± 1 106 ± 2 0.24 ± 0.01 0.25 ± 0.0
Lipoid Lot 1 101 ± 2 100 ± 2 0.27 ± 0.01 0.25 ± 0.0
Lot 2 86 ± 1 88 ± 2 0.27 ± 0.01 0.27 ± 0.0
Avanti Lot 1 87 ± 1 85 ± 1 0.22 ± 0.01 0.21 ± 0.0
Lot 2 93 ± 1 93 ± 1 0.26 ± 0.01 0.25 ± 0.0(Avanti Polar Lipids Inc., Corden Pharma, Lipoid LLC,
and NOF Corporation). HPLC-CAD traces show only a
single peak for the raw material from all four suppliers,
indicating that DPPC purity was comparable among the
different manufacturers (Figure 1). In addition, the phys-
icochemical stability indicators of all batches of GLA-AF
were also comparable. All eight batches were stable ac-
cording to the criteria described above regarding visual
appearance, particle size, and GLA concentration over
6 months (Table 1). Since GLA-AF in this case was proc-
essed via bath sonication, particle size was not tightly re-
producible between different lots, as expected due to the
inherent difficulty with bath sonication. Thus, even when
processed in the exactly same manner, different lots
containing the same excipients could result in slightly
different particle size, but all batches remained in the
range of 81–106 nm. There were also slight variations inysicochemical stability
Measured GLA concentration (μg/ml) [250 ± 50 μg/ml target]
DM 6 mo
1 222 ± 6 200 ± 3
4 206 ± 2 166 ± 2
1 209 ± 10 179 ± 5
1 206 ± 3 171 ± 11
1 230 ± 3 210 ± 3
3 212 ± 4 197 ± 2
1 261 ± 4 231 ± 2
1 223 ± 2 234 ± 2
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Figure 2 (See legend on next page.)
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Figure 2 Characterization of pH and size stability of GLA-AF with various buffer compositions. (a) pH of buffered GLA-AF’s at the following
time points: DM, 1 week, 2 weeks, 1 month, 3 months, 6 months. (b) Particle size of buffered GLA-AF compositions measured at DM, 1 week, 2 weeks,
1 month, 3 months, and 6 months. (c) Polydispersity index (PdI) of buffered GLA-AF compositions measured at DM, 1 week, 2 weeks, 1 month,
3 months, and 6 months. GLA-AF made with ammonium phosphate at 20 or 25 mM, citric acid, or PBS failed to maintain particle size within 50% of
the DM value before reaching the 6-month timepoint, thus pH, size, and PdI data for those lots were measured until (and including) the time point at
which their size failed this specification.
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lots, but those variations show no correlation to DPPC
manufacturers. a
bInfluence of buffer composition on physicochemical stability
Since GLA-AF is formulated by rehydrating the GLA
and DPPC mixture in water, the formulation is not pro-
tected from fluctuations in pH, which could result in com-
ponent degradation. In an attempt to maintain pH control,
the following buffers were employed as the aqueous phase:
ammonium phosphate (5, 12.5, 20, 25 mM, pH ~5.5);
citric acid (10 mM, pH 6.1); phosphate-buffered saline
(composed of 1.5 mM monobasic potassium phosphate,
155 mM sodium chloride, and 2.7 mM dibasic sodium
phosphate, at pH 7.2; or 41 mM monobasic potassium
phosphate, 103 mM sodium chloride, and 9 mM dibasic
sodium phosphate, at pH 6.1); HEPES (10 mM, pH 7);
HEPES-buffered saline (10 mM HEPES, 154 mM NaCl,
pH 7). These various buffers were tested to determine
the most favorable buffer composition, pH condition, and
salt concentration for GLA-AF formation and stability. The
formulation pH was monitored to evaluate whether the
buffer provided pH control. Along with the standard physi-
cochemical characteristics mentioned above, pH was mea-
sured on the DM, at 1 week, 2 weeks, 1 month, 3 months,
and 6 months. The pH values of all buffers that were com-
patible with GLA-AF formation showed no more than aTable 2 GLA concentration of buffered
GLA-AF compositions
Aqueous phase compositions
and concentrations (mM)
Measured GLA concentration
(μg/ml) [1000 ± 200 μg/ml target)
DM 6 mo
Ammonium phosphate (5) 737 ± 34 715 ± 34
Ammonium phosphate (12.5) Lot 1 861 ± 21 791 ± 21
Ammonium phosphate (12.5) Lot 2 860 ± 24 N/A
Ammonium phosphate (20) 920 ± 13 N/A
Ammonium phosphate (25) 982 ± 15 N/A
Citric acid (10) 886 ± 14 N/A
Phosphate buffered saline (50), pH 6.1 960 ± 18 N/A
HEPES (10) 945 ± 25 912 ± 28
Water Lot 1 864 ± 28 992 ± 8
Water Lot 2 930 ± 14 773 ± 6
Figure 3 Microfluidization processing effects on size
characteristics of GLA-AF. (a) Effect of microfluidizing pressure and
number of discrete passes on unbuffered GLA-AF particle size
(0.1 mg/ml GLA target concentration). (b) Effect of microfluidizing
pressure and number of discrete passes on unbuffered GLA-AF size
polydispersity index. Two batches were manufactured at each
pressure and monitored for size and PdI at 0, 2, 5, 10, 15, and 20
passes with the exception of one of the 10,000 psi batches where
the 2nd pass measurement was missed so a 3rd batch was manufactured
at 10,000 psi and measured at 0, 2, and 5 passes only.
Table 3 Effect of microfluidization processing on unbuffered GLA-AF recovery and physicochemical stability
Processing
pressure (psi)
Target GLA
concentration (μg/ml)
# Passes Particle size (Z-ave, nm) Pdl Measured GLA concentration
DM T = 6 mo DM T = 6 mo T = DM or 3 mo T = 6 mo
10, 000 100 20 128 ± 3 - 0.25 ± 0.03 - - -
20 156 ± 4 - 0.41 ± 0.03 - 50 ± 0 -
20, 000 100 20 58 ± 2 56 ± 1 0.24 ± 0.01 0.23 ± 0.02 90 ± 2 88 ± 4
20 118 ± 1 - 0.27 ± 0.00 - 72 ± 4 -
30, 000 100 20 81 ± 2 92 ± 1 0.44 ± 0.02 0.47 ± 0.04 85 ± 2 87 ± 3
20 100 ± 11 92 ± 2 0.28 ± 0.06 0.40 ± 0.02 104 ± 1 84 ± 3
250 15 133 ± 3 - 0.29 ± 0.01 - 231 ± 8 -
250 15 58 ± 1 - 0.25 ± 0.02 - 232 ± 6 -
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tion became unstable by particle size (Figure 2a). The un-
buffered GLA-AF, with ultrapure water as its aqueous
phase, showed only a slightly higher pH shift of 0.34 after
6 months, although it is unclear if this magnitude is sig-
nificant since temperature was not tightly controlled for
the pH measurements. Large visible particles still existed
in preparations containing GLA and DPPC in PBS at
pH 7.2 or HEPES-buffered saline at pH 7 even after
3 hours of sonication, so these formulations were not eva-
luated further regarding physicochemical characteristics
or stability.
There were interesting differences regarding the influ-
ence of buffer composition on GLA-AF particle size stabil-
ity (Figure 2b). GLA-AF made with ammonium phosphate
at 20 or 25 mM, citrate, or PBS at pH 6.1 failed before
6 months due to not meeting the particle size criteria
of <50% change from the DM value. Likewise, these for-
mulations showed increased PdI values correlating with
their increased particle size (Figure 2c). Some buffered and
unbuffered formulations were stable with regards to par-
ticle size (<50% change) as well as visual appearance, al-
though the particle size of the GLA-AF containing 5 mM
ammonium phosphate buffer and the GLA-AF containing
10 mM HEPES indicated gradual increase in size over
6 months. Moreover, some variability between batches
of the same composition should be taken into account,Table 4 Effect of microfluidization processing on GLA-AF reco
12.5 mM ammonium phosphate
Processing
pressure (psi)
# Passes Particle size (Z-ave, nm) Pdl
DM T = 6 mo DM
20, 000 2 99 ± 3 108 ± 2 0.21 ± 0.01
5 99 ± 4 - 0.25 ± 0.02
10 96 ± 1 124 ± 5 0.26 ± 0.01
30, 000 2 99 ± 3 93 ± 1 0.21 ± 0.01
5 67 ± 1 - 0.22 ± 0.01
10 68 ± 1 84 ± 2 0.27 ± 0.02since the first batch of GLA-AF buffered at 12.5 mM am-
monium phosphate showed little change in size or PdI
over 6 months, but a second batch with the same
composition demonstrated gradual particle size growth,
eventually achieving >50% of initial size by the 6-month
timepoint. Chemical stability of GLA changed less than
20% in all formulations that demonstrated stable particle
size over 6 months (Table 2). However, the DM GLA con-
centration for the formulation containing ammonium
phosphate buffer at 5 mM was not within 20% of the initial
targeted GLA concentration of 1000 μg/ml (possibly indi-
cating some difficulty in efficient dispersion of all of the
GLA during sonication).
Influence of manufacturing process on
physicochemical stability
To evaluate the effects of different microfluidization
parameters on the physicochemical characteristics of
GLA-AF, we focused on the most stable compositions from
the buffer evaluation experiment described above, including
unbuffered GLA-AF or GLA-AF containing 12.5 mM am-
monium phosphate. Various processing pressure and cyc-
ling time (i.e. number of passes) conditions were employed,
and the resulting effects on particle size and GLA concen-
tration over 6 months monitored for unbufferd GLA-AF
(Figure 3, Table 3) and buffered GLA-AF (Table 4). Due
to cost and material use concerns associated with thevery and physicochemical stability when buffered with
Measured GLA concentration [100 ± 20 μg/ml target]
T = 6 mo DM T = 6 mo
0.32 ± 0.01 89 ± 1 96 ± 5
- - -
0.53 ± 0.02 113 ± 4 94 ± 2
0.37 ± 0.02 89 ± 2 96 ± 5
- - -
0.37 ± 0.02 105 ± 1 88 ± 3
Figure 4 In vitro cytokine production activity elicited by GLA-AF. (a) MIP-1β production by Mono Mac 6 cells stimulated with unbuffered GLA-AF man-
ufactured with DPPC from different suppliers. (b) MIP-1β production by Mono Mac 6 cells stimulated with unbuffered GLA-AF manufactured by different
processes. (c) MIP-1β production by human whole blood stimulated with unbuffered GLA-AF manufactured with DPPC from different suppliers. (d) MIP-1β
production by human whole blood stimulated with unbuffered GLA-AF manufactured by different processes. (e) IL-12p40 production by human whole
blood stimulated with unbuffered GLA-AF manufactured with DPPC from different suppliers. (f) IL-12p40 production by human whole blood stimulated with
unbuffered GLA-AF manufactured by different processes. For all plots, error bars represent standard error of the mean, based on six values (sera from three
volunteers assayed in duplicate) and note that one of the GLA-AF batches employed in these studies is not the same one represented in Table 1.
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Figure 5 In vivo adjuvant activity elicited by PbCSP antigen with GLA-AF. (a) Antibody endpoint titers measured two weeks after the
second immunization. Each group consisted of 4–5 mice immunized with 1 μg GLA-AF and 2 μg PbCSP. Each of the adjuvanted groups achieved
statistical significance in IgG2c titers compared to PbCSP alone (p < 0.05). No other statistical differences between groups were apparent. (b)
Cytokine ELISAs of splenocytes collected six weeks after the third immunization and stimulated with antigen. Each group consisted of 5 mice
immunized with 1 μg GLA-AF and 2 μg PbCSP, with each value consisting of an average of two duplicates. No statistical differences between
groups were present. (c) Splenocytes producing cytokines six weeks after the third immunization, detected by ELISPOT assay. Each group
consisted of 5 mice immunized with 1 μg GLA-AF and 2 μg PbCSP, with each value consisting of an average of two duplicates. The number of
IFNγ-producing cells from the PbCSP + GLA-AF Avanti group acheived statistical significance (p < 0.05) compared to PbCSP alone, PbCSP + GLA-AF
NOF, and PbCSP + GLA-AF Lipoid. No other statistical differences between groups were apparent.
Fung et al. Journal of Nanobiotechnology 2013, 11:43 Page 11 of 12
http://www.jnanobiotechnology.com/content/11/1/43microfluidizing process requiring large minimum batch
volumes (~80 ml), GLA-AF was generally manufactured
at more dilute concentrations compared to the sonicated
batches above. Apparently very few passes are necessary
to form small particle sizes (~100 nm) at 20,000 psi or
30,000 psi, whereas higher number of passes did not
reproducibly reduce size further and could even result
in larger size. Likewise, polydispersity index often in-
creased with higher numbers of passes. Both unbuffered
and ammonium phosphate-buffered compositions ap-
peared amenable to microfluidization, although there was
some growth in particle size for the buffered GLA-AF.
The 10,000 psi batch of unbuffered GLA-AF where GLA
was quantified resulted in only ~50% recovery of GLA
after 20 passes (the GLA recovery was ~55% after 5
passes, so most of the GLA was lost early in the process).
All of the batches manufactured at 20,000 psi or
30,000 psi resulted in successful recovery of the GLA
(within 20% of target value, Tables 3 and 4), with the ex-
ception of one unbuffered 20,000 psi batch. Furthermore,
we attempted manufacture of two batches at the higher
target concentration of 0.25 mg/ml GLA processed at
30,000 psi which demonstrated successful GLA recovery
but some variation in size between batches (Table 3). We
note that lower concentration GLA-AF batches were also
successfully manufactured for use in the in vivo bioactivity
evaluation described below. Thermal phase transition pro-
files between sonicated and microfluidized GLA-AF
batches are broad overall, but sonicated batches appear to
have a slightly higher phase transition peak than micro-
fluidized batches, indicating that the phase structure of
the GLA-DPPC complexes may be somewhat altered by
the different processing conditions (Additional file 1:
Figure S1).
In vitro biological activity
Macrophage inflammatory protein-1β (MIP-1β; also known
as CCL4) is a chemoattractant for various immune cells.
The production of MIP-1β by the human macrophage cell
line, Mono Mac 6, is being developed in our laboratory
as a quality control assay for TLR4 agonists due to lin-
earity and reproducibility [9]. Consistent with the similar
physicochemical characteristics measured for each distinct
formulation, no differences were observed in MIP-1βproduction by Mono Mac 6 cells stimulated either by
batches of GLA-AF made with DPPC from four different
suppliers (Figure 4a) or by different processes (Figure 4b).
Stimulation of unfractionated human blood yielded similar
results in terms of MIP-1β production (Figure 4c and 4d).
Production of IL-12, a cytokine critical for development of
antigen-specific inflammatory responses was also compa-
rable across the different GLA-AF formulations (Figures 4e
and 4f). There was an indication of greater batch variation
in the sonicated GLA-AF than the microfluidized
GLA-AF. Refined evaluation of additional batches is re-
quired to assess this possibility, which could indicate
that microfluidization produces a more uniform, rep-
roducible formulation than sonication.
In vivo biological activity
To determine how GLA-AF formulation parameters in-
fluenced qualitative antigen-specific immune responses,
we immunized mice (n = 4-5) with recombinant protein
(PbCSP) mixed into various GLA-AF formulations. As
expected, PbCSP immunization raised antigen-specific
IgG and administration with adjuvant elevated these re-
sponses only marginally. Upon further analyses, it was
evident that, while antigen-specifc IgG1 responses were
unaltered, inclusion of any of the various GLA-AF sig-
nificantly increased IgG2c antibody titers compared to
administration of the antigen alone (Figure 5a). These
data are indicative of the Th1-biasing activity of GLA-
containing formulations. This observation was corrobo-
rated by analyses of the cellular responses. Antigen-specific
recall responses demonstrated a trend of IL-5 secretion re-
duction and IFN-γ secretion enhancement in mice immu-
nized with GLA-AF formulations relative to mice treated
with protein alone (Figure 5b). Similar observations were
made when the number of IL-5 and IFN-γ secreting cells
were determined (Figure 5c). Taken together, the pat-
tern of antibody and cellular responses indicate that
each of the GLA-AF evaluated is capable of biasing to-
ward antigen-specific Th1 responses. Thus, excipient
source and manufacturing method did not appear to
alter the qualitative immunogenicity response induced
by the adjuvanted vaccine. These data, generated with a
1 μg dose GLA, are consistent with our previous reports
generated using higher (5–20 μg) doses [9].
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imal impact on the physicochemical characteristics and
biological activity of GLA-AF. Buffered compositions
may have slightly decreased the tendency for pH drift
over time, but overall these resulted in decreased particle
size stability compared to unbuffered GLA-AF. Micro-
fluidization resulted in rapid particle size reduction after
only a few passes, and 20,000 or 30,000 psi processing
pressures were more effective at reducing particle size
than 10,000 psi. Microfluidized batches maintained good
particle size and chemical (GLA concentration) stability
over 6 months, without significantly altering in vitro bio-
activity of GLA-AF or in vivo bioactivity of GLA-AF
when combined with a recombinant vaccine antigen. How-
ever, some microfluidization batches resulted in lower re-
covery of GLA depending on process pressure. We note
here that concentrations of GLA > 0.04 mg/ml are unlikely
to be necessary in large scale batches given the low clinical
doses employed (≤10 μg). GLA-AF is currently being eva-
luated as a vaccine adjuvant formulation in various phase I
clinical trials. Microfluidization may be an effective manu-
facturing process to improve the scalability and reproduci-
bility of GLA-AF as it advances further in the clinical
development pathway. Process optimization work inclu-
ding temperature control is ongoing in our lab and may be
applicable to other nanosuspension-based formulations.
Additional file
Additional file 1: Figure S1. Differential scanning calorimetry scans of
microfluidized or sonicated GLA-AF.
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